Invesco Biotechnology & Genome ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Invesco Biotechnology & Genome ETF PBE
Morningstar’s Analysis PBE
Will PBE outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Illumina Inc | 6.08 | 27M | Healthcare |
Natera Inc | 5.97 | 26M | Healthcare |
Biogen Inc | 5.60 | 25M | Healthcare |
Gilead Sciences Inc | 5.23 | 23M | Healthcare |
Royalty Pharma PLC Class A | 5.15 | 23M | Healthcare |
Amgen Inc | 4.96 | 22M | Healthcare |
Regeneron Pharmaceuticals Inc | 4.79 | 21M | Healthcare |
Vertex Pharmaceuticals Inc | 4.61 | 20M | Healthcare |
Moderna Inc | 3.50 | 15M | Healthcare |
Halozyme Therapeutics Inc | 3.14 | 14M | Healthcare |